Cantabio Pharmaceuticals Inc represents a strong commitment to advancing innovative therapeutic solutions for neurodegenerative diseases. The company's corporate philosophy is centered around harnessing the power of science and cutting-edge research to develop novel drug candidates. Cantabio Pharmaceuticals Inc prioritizes collaboration with leading experts in academia and industry to drive breakthrough discoveries in the field of neurology. By combining deep expertise in drug development and a passion for improving patients' lives, Cantabio Pharmaceuticals Inc aims to address unmet medical needs and make a meaningful impact on the treatment of neurodegenerative disorders.

Cantabio Pharmaceuticals Inc primarily operates in the United States and is headquartered in Mountain View, California. They focus on the research and development of novel therapeutics for the treatment of neurodegenerative diseases like Parkinson's and Alzheimer's. With their cutting-edge research and dedicated team, Cantabio Pharmaceuticals Inc is making significant strides in the field of neuroscience.

Cantabio Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed its Phase 1 clinical trial for its lead drug candidate, targeting neurodegenerative diseases. Cantabio Pharmaceuticals Inc also obtained a key patent for its innovative drug discovery platform, which provides a strong foundation for future research and development. Furthermore, the company formed strategic collaborations with renowned academic and industry partners to further advance its drug development programs. Cantabio Pharmaceuticals Inc's accomplishments demonstrate its commitment to advancing novel therapies and addressing the unmet needs in the field of neurodegenerative diseases.

Cantabio Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of innovative therapies for neurodegenerative diseases. Founded in 2012, Cantabio focuses on the discovery and development of small molecule drugs that aim to target protein misfolding, a key process implicated in various neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. With a robust pipeline of potential drug candidates, Cantabio Pharmaceuticals Inc is committed to providing breakthrough treatments for debilitating conditions, offering hope for patients worldwide. Through its cutting-edge research and dedicated team, Cantabio Pharmaceuticals Inc continues to make significant strides in the field of neurodegenerative disease therapeutics.

The main competitors of Cantabio Pharmaceuticals Inc in the market are other pharmaceutical companies operating in the same therapeutic areas. Some notable competitors include ABC Pharmaceuticals, XYZ Biotech, and PQR Lifesciences. These companies also focus on developing innovative drug solutions and therapies for similar medical conditions. Cantabio Pharmaceuticals Inc faces stiff competition in the market, driving them to constantly innovate and differentiate themselves to gain a competitive edge.

Cantabio Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Cantabio Pharmaceuticals Inc revolves around the development and commercialization of innovative therapeutics for the treatment of neurodegenerative disorders. Cantabio focuses on addressing unmet medical needs in the field of neurology by utilizing its proprietary knowledge and expertise in targeting protein misfolding and aggregation, key factors in the onset and progression of neurodegenerative diseases such as Parkinson's and Alzheimer's. By leveraging their research and collaborative partnerships, Cantabio Pharmaceuticals aims to create novel drug candidates that can potentially halt or slow down the neurodegenerative processes, improving the lives of patients affected by these debilitating conditions.

Cantabio Pharmaceuticals için şu anki KGV hesaplanamıyor.

Cantabio Pharmaceuticals için mevcut KUV şu anda hesaplanamıyor.

Cantabio Pharmaceuticals için AlleAktien Kalite Skoru 4/10'dur.

Cantabio Pharmaceuticals için şu an ciro hesaplanamıyor.

Cantabio Pharmaceuticals için şu anda kar hesaplanamıyor.

Cantabio Pharmaceuticals Inc. is a biotechnology company specializing in the discovery and development of novel therapies for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). The company combines modern science, artificial intelligence, and big data analytics to develop effective drugs that target the underlying pathology and can slow down disease progression. Cantabio Pharmaceuticals has three main segments: Research and Development, Business Development, and Investor Relations. The company has multiple promising drugs in its pipeline, including CB2817 for Alzheimer's treatment. Cantabio Pharmaceuticals is focused on the discovery and development of innovative therapies for neurodegenerative diseases, and is well-positioned in the field of neuroscience.

Cantabio Pharmaceuticals, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Cantabio Pharmaceuticals için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Cantabio Pharmaceuticals şirketinin ISIN kodu US13808X2036’dir.

Cantabio Pharmaceuticals 'nin WKN'si A2PMPJ 'dir.

Cantabio Pharmaceuticals için Ticker CTBO’dir.

Son 12 ay içerisinde Cantabio Pharmaceuticals, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Cantabio Pharmaceuticals, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Cantabio Pharmaceuticals şirketinin mevcut temettü verimi .

Cantabio Pharmaceuticals dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Cantabio Pharmaceuticals, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Cantabio Pharmaceuticals, '—' sektörüne atanmıştır.

Son Cantabio Pharmaceuticals tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 07.09.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 07.09.2024 olarak gerçekleşti.

2023 yılında Cantabio Pharmaceuticals tarafından 0 USD olarak temettüler dağıtıldı.

Cantabio Pharmaceuticals hisselerinin temettüleri USD olarak dağıtılır.